Among the new therapeutic strategies, NBI-921352 (formerly known as XEN901), a selective Nav1.6 inhibitor, has been designed to treat early infantile epileptic encephalopathy resulting from GoF SCN8A mutations. Here, SCN8A is linked to Epileptic encephalopathy.